Savara announces manuscript on long-term outcomes with molgramostim inhalation solution (molgramostim) in autoimmune pulmonary alveolar proteinosis (apap) published in erj open research

Langhorne, pa.--(business wire)--savara inc. (nasdaq: svra) (the company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced a manuscript titled, “long-term outcomes in five patients with autoimmune pulmonary alveolar proteinosis treated with molgramostim inhalation solution" was published online in the journal erj open research. the outcomes data presented suggest that treatment with molgramostim addresses the underlying pathophysiology of apap, r.
SVRA Ratings Summary
SVRA Quant Ranking